Natera, INC Form 4 insider transactions

Natera's President and Chief Business Officer, John Fesko, sold shares to cover tax obligations following the vesting of restricted stock units.

Natera, Inc. Co-Founder and Director Jonathan Sheena sold over $958,000 worth of company common stock through pre-arranged trading plans.

Natera's CEO and President, Steven Leonard Chapman, sold 5,807 shares of common stock in early August 2025 under a pre-arranged trading plan.

Natera, Inc. Director Gail Boxer Marcus sold 2,496 shares of common stock for approximately $332,300 through a pre-arranged trading plan.

Natera's President of Clinical Diagnostics, Solomon Moshkevich, sold 3,000 shares of common stock in pre-planned transactions.

Natera, Inc. CEO and President Steven Leonard Chapman sold 6,092 shares of common stock for approximately $140 per share to cover tax withholding related to RSU vesting, as part of a pre-arranged 10b5-1 plan.

Natera Inc.'s Chief Financial Officer, Michael Burkes Brophy, sold 5,064 shares of common stock across multiple transactions in late July 2025, primarily under a pre-established Rule 10b5-1 trading plan.

Natera, Inc. Director and Co-Founder Jonathan Sheena sold 479 shares of common stock for $139.8083 per share to cover tax obligations related to RSU vesting.

Natera's Executive Chairman, Matthew Rabinowitz, sold 1,718 shares of common stock for $139.8083 per share to cover tax obligations related to RSU vesting, as disclosed in a Rule 10b5-1(c) plan.

Natera's President of Clinical Diagnostics, Solomon Moshkevich, sold 2,206 shares of common stock to cover tax withholding related to RSU vesting, as part of a Rule 10b5-1 plan.

Natera's President and Chief Business Officer, John Fesko, sold 1,710 shares of common stock to cover tax obligations related to RSU vesting.

Natera's SEC and Chief Legal Officer, Daniel Rabinowitz, sold 1,994 shares of common stock to cover tax obligations related to RSU vesting, as disclosed in a recent Form 4 filing.

Natera, Inc. Director Brinkley Ruth Williams received 112 shares of common stock through Restricted Stock Units as compensation for board service, aligning her interests with shareholders.

Natera, Inc. Director Herm Rosenman acquired 153 shares of common stock through Restricted Stock Units as part of his quarterly retainer fees.

Natera, Inc. Director Gail Boxer Marcus acquired 141 fully vested Restricted Stock Units as compensation for Board service, aligning her interests with shareholders.

Natera, Inc. Director Roelof Botha acquired 173 shares of common stock through a Restricted Stock Unit grant in lieu of quarterly retainer fees.

Natera, Inc. Director Monica Bertagnolli was issued 108 fully vested Restricted Stock Units as compensation for her board service, increasing her direct beneficial ownership to 5,128 shares.

Natera, Inc. Director Roy D. Baynes acquired 108 shares of common stock through a fully vested Restricted Stock Unit grant on July 25, 2025, increasing his total beneficial ownership to 18,266 shares.

Natera's Chief Financial Officer, Michael Burkes Brophy, reported multiple stock transactions including the vesting of Restricted Stock Units and subsequent sales, primarily under a pre-arranged 10b5-1 trading plan and for tax obligations.

Natera's Chief Financial Officer, Michael Burkes Brophy, exercised Restricted Stock Units and subsequently sold a portion of the resulting common stock to cover tax withholding obligations.

Natera, Inc. CEO Steven Chapman reported the vesting of 3,386 Restricted Stock Units and a subsequent sale of 1,622 shares to cover tax obligations.

Natera's SEC and Chief Legal Officer, Daniel Rabinowitz, executed multiple stock sales totaling over $3.4 million in June and July 2025, primarily under a Rule 10b5-1 trading plan.

Natera Co-Founder and Director Jonathan Sheena reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations, executed under a pre-arranged trading plan.

Natera's President of Clinical Diagnostics, Solomon Moshkevich, sold shares totaling approximately $299,096 to cover tax withholding obligations related to RSU vesting.

Natera's President and Chief Business Officer, John Fesko, executed two pre-planned sales of common stock totaling 1,777 shares to satisfy tax withholding obligations related to the vesting of Restricted Stock Units.

Natera, Inc. Director and Co-Founder Jonathan Sheena has filed a Form 4 indicating a future sale of 3,070 shares of common stock on July 16, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Natera, Inc. Director and Co-Founder Jonathan Sheena sold 3,000 shares of common stock on July 2, 2025, through pre-arranged Rule 10b5-1 trading plans.

Natera, Inc. CEO and President Steven Leonard Chapman sold 5,343 shares of common stock on July 1, 2025, through a pre-arranged Rule 10b5-1 trading plan.

Natera, Inc.'s President of Clinical Diagnostics, Solomon Moshkevich, sold 3,000 shares of common stock on July 1, 2025, through a pre-arranged Rule 10b5-1 trading plan.

A Natera, Inc. director exercised stock options and subsequently sold an equivalent number of common shares on July 1, 2025, under a pre-arranged 10b5-1 trading plan.